Shockwave Medical to Present at the Canaccord Genuity 41st Annual Growth Conference

Rhea-AI Summary

Shockwave Medical, a leader in Intravascular Lithotripsy (IVL) technology for treating calcified cardiovascular disease, announced its participation in the Canaccord Genuity 41st Annual Growth Conference from August 10-12, 2021. Management will engage in a live fireside chat on August 11, 2021, at 11:30 a.m. Eastern Time. The event will be accessible via a live and archived webcast on the company’s website. Shockwave Medical aims to redefine treatment standards for atherosclerotic cardiovascular disease by enhancing patient outcomes with their innovative IVL technology.

SANTA CLARA, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Canaccord Genuity 41st Annual Growth Conference, scheduled to be held virtually August 10 to 12, 2021.

Shockwave's management is scheduled for a live fireside chat on Wednesday, August 11, 2021, at 11:30 a.m. Eastern Time. Interested parties may access a live and archived webcast of the event on the "Investors" section of the company’s website at https://ir.shockwavemedical.com.

About Shockwave Medical, Inc.

Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit www.shockwavemedical.com.

Media Contact:
Rob Fletcher
rfletcher@shockwavemedical.com

Investor Contact:
Debbie Kaster
dkaster@shockwavemedical.com

FAQ

What is the date of Shockwave Medical's participation in the Canaccord Genuity conference?

Shockwave Medical will participate in the Canaccord Genuity 41st Annual Growth Conference from August 10 to 12, 2021.

When is Shockwave Medical's live fireside chat scheduled?

The live fireside chat for Shockwave Medical is scheduled for August 11, 2021, at 11:30 a.m. Eastern Time.

Where can I access the webcast of Shockwave Medical's conference participation?

The webcast for Shockwave Medical's conference participation can be accessed on the company's website under the 'Investors' section.

What is Intravascular Lithotripsy (IVL) technology?

Intravascular Lithotripsy (IVL) is a technology developed by Shockwave Medical to treat calcified cardiovascular disease through localized sonic pressure waves.

What are the goals of Shockwave Medical concerning cardiovascular disease treatment?

Shockwave Medical aims to transform treatment standards for atherosclerotic cardiovascular disease and improve patient outcomes with their IVL technology.